ITC Takes Medytox’s Hand In US Botulinum Case, Bans Daewoong’s Imports
Executive Summary
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll on the Korean firm and partner Evolus as they face a 10-year ban on imports of their product to the US.